WEKO3
アイテム
FLT-PET/CT for Lung Cancer Patients Receiving Carbon-Ion Radiation Therapy: Prognostic Significance
https://repo.qst.go.jp/records/69894
https://repo.qst.go.jp/records/698947bacdc11-7c6e-4e90-b4e7-e30f3723f0c4
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2009-10-17 | |||||
| タイトル | ||||||
| タイトル | FLT-PET/CT for Lung Cancer Patients Receiving Carbon-Ion Radiation Therapy: Prognostic Significance | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Saga, Tsuneo
× Saga, Tsuneo× Koizumi, Mitsuru× Inubushi, Masayuki× Yoshikawa, Kyosan× Fukumura, Toshimitsu× Baba, Masayuki× 佐賀 恒夫× 小泉 満× 犬伏 正幸× 吉川 京燦× 福村 利光× 馬場 雅行 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Aim: To investigate the prognostic significance of positron emission tomography (PET) using F-18-fluorothymidine (FLT), a tracer for cellular proliferation, for lung cancer patients receiving carbon-ion radiation therapy (CIRT). Materials & Methods: Twenty-one consecutive patients (mean age 73 years, 12 male and 9 female) with lung cancer who are going to be treated with CIRT received FLT-PET/CT before and 3 months after CIRT. Fifty minutes after intravenous injection of approximately 300 MBq of FLT, PET/CT data were acquired. Maximal standardized uptake value (SUVmax) of the tumor was measured by using CT image as a reference of ROI placement. Reduction rate of tumor uptake was also calculated (RR = (pre-SUVmax – post-SUVmax)/pre-SUVmax). Patients were followed for the development of recurrence and/or metastasis (follow-up period: 8 – 29 months). The study plan was approved by the Institutional Ethical Committee and informed consent was obtained from all patients before FLT-PET examination. Results: Squamous cell carcinomas tended to show higher FLT uptake than adenocarcinomas, but the difference was not statistically significant (3.70 +/- 1.88 versus 2.85 +/- 1.55, p=0.27). Two patients were excluded from the follow up study because of the presence of liver metastasis before CIRT in one case and the detection of second malignancy (gastric cancer) in the follow-up period in the other case. Seven of 19 patients developed recurrence and/or metastasis in the follow-up period determined by histological analysis in 3 cases and by clinical follow-up including various imaging modalities in 4 cases, and 4 of these 7 patients died. Patients who developed recurrence and/or metastasis showed higher pre-SUVmax than those who did not develop recurrence and/or metastasis (3.90 +/- 1.33 versus 2.54 +/- 1.38, p=0.051). Post-SUVmax and RR did not show any significant difference between the two groups (p=0.633 and 0.111, respectively). Kaplan-Meier analysis showed that pre-SUVmax threshold of 3.7 best discriminated patients having favorable post-CIRT course from those having unfavorable post-CIRT course (p=0.004 for progression-free survival and p=0.011 for overall survival). Conclusion: Although the number of patients is small and the follow up period is not long enough, the present data suggests the prognostic significance of FLT-PET performed prior to treatment in lung cancer patients being treated with CIRT. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Annual Congress of the European Association of Nuclear Medicine 2009 | |||||
| 発表年月日 | ||||||
| 日付 | 2009-10-14 | |||||
| 日付タイプ | Issued | |||||
